Core Viewpoint - The statement from China Coal Mining Group emphasizes the completion of the transfer of 90% equity in China Energy Investment Management (Tianjin) Co., Ltd. to China New Energy Holdings Group, clarifying that China Coal Mining no longer holds any equity or control over the company [1][2]. Group 1 - After the equity transfer, China Coal Mining no longer has any shareholding or control relationship with China Energy Tianjin [1]. - China Coal Mining was a founding shareholder of China Energy Tianjin, but the public records may still show it as a historical shareholder, which could lead to misinterpretation by the public and investors [1]. - China Coal Mining has never authorized China Energy Tianjin or its subsidiaries to use any related trademarks or intangible assets, and it does not take responsibility for any actions taken by China Energy Tianjin [1][2]. Group 2 - China Energy Tianjin and its subsidiaries have repeatedly used the "China Coal" series of trademarks and related rights without authorization, constituting serious infringement [2]. - China Coal Mining demands that China Energy Tianjin and its subsidiaries immediately cease any activities using the "China Coal" series of trademarks and related assets [2]. - The company will pursue legal responsibility for any impersonation or forgery related to the "China Coal" association [2].

Core Viewpoint - China National Pharmaceutical Group announced the transfer of 25% equity in China National Medicine Co., Ltd. to Shanghai Tianyue Tenghua Trading Service Co., Ltd., resulting in no remaining equity or control relationship between the parties involved [1][2]. Summary by Sections Equity Transfer - The equity transfer will be completed by September 30, 2025, in the national property management information system, after which China National Medicine will no longer hold any shares in the pharmaceutical materials company [1][2]. Historical Context - China National Medicine was a founding shareholder of the pharmaceutical materials company, which may still be reflected in public records, leading to potential misinterpretations by the public and investors [2]. Unauthorized Use of Assets - The pharmaceutical materials company has repeatedly used the trademarks and intangible assets of China National Pharmaceutical Group without authorization, constituting serious infringement, and legal actions have been initiated to pursue accountability [3]. Legal Actions and Warnings - The company demands the immediate cessation of any unauthorized use of its trademarks and assets by the pharmaceutical materials company and warns of legal consequences for any impersonation or false association with China National Pharmaceutical Group [3].